C2N Diagnostics’ Post

View organization page for C2N Diagnostics, graphic

6,928 followers

Publication Alert! Alzheimer's & Dementia has published important research that used C2N Diagnostics’ PrecivityAD® blood test to measure study participants’ Aβ42/40 ratios and ApoE proteotypes. The paper is titled “Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial.” The authors wrote that “Our findings highlight the potential importance of plasma biomarker screening tests (Aβ42/40, p-tau species, etc.) in assembling a more inclusive and diverse cohort for [Alzheimer’s disease] clinical trials.” The researchers also stated that “current analysis suggests that the plasma Aβ42/40 values reflect brain amyloid consistently across [underrepresented groups].” https://lnkd.in/eBf4ixSm #precisionmedicine #Alzheimersdisease #research #racialdifferences #dementia #preclinical #study

To view or add a comment, sign in

Explore topics